Benitec Biopharma Inc. (BNTC) Stock

Benitec Biopharma Inc. (BNTC) is a Healthcare stock trading at $13.53 (as of 2026-08-21), with a market capitalization of $464.64M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Benitec Biopharma Inc. is a biotechnology company developing genetic medicines, including DNA-directed RNA interference therapeutics for chronic and life-threatening human conditions. Its pipeline includes BB-301, an adeno-associated virus gene therapy for oculopharyngeal muscular dystrophy, and BB-103 for chronic hepatitis B.

Understand Benitec Biopharma Inc.: how it makes money

Benitec Biopharma develops DNA-directed RNA interference based genetic medicines, including the gene therapy agent BB-301 for oculopharyngeal muscular dystrophy and BB-103 for chronic hepatitis B, and it has 0.0B of reported revenue in the provided 2023-03-31 period.

For a development-stage gene therapy company like Benitec, the path to future profits depends on progressing specific clinical programs (for example BB-301 cohort results), because near-term economics are driven by trial advancement rather than current product sales.

Business quality (Weak): Clear clinical focus (BB-301 and BB-103) with reported cohort outcome metrics, but the company shows no reported revenue in the provided period and operating profitability is deeply negative, so results must translate into continued clinical progress and, ultimately, approval.

Bull case

  • BB-301 Cohort 1 reported a 100.0% responder rate: If sustained and confirmed in broader cohorts, that pattern of response is a key clinical signal for BB-301.
  • Reported swallowing-related questionnaire sub-score reductions for BB-301: The provided data includes reductions across thin-liquid, repeat-swallow necessity, and other swallow categories for specific subjects.

Bear case

  • Small cohort size in the provided snapshot: Cohort 1 shows only 4.0 patients enrolled, with 6.0 cohort completers identified as formal responders in the provided facts, which can increase uncertainty around how representative the results are.
  • No reported revenue and very negative operating margin in the provided period: With 0.0B reported revenue for 2023-03-31 and an operating margin of -8038.9, the business has not demonstrated commercial scale in the provided data.
Valuation — source: SEC EDGAR (first-party)
Price$13.53
Market Cap$464.64M
Price / Book2.53
FCF Yield-7.3%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$0.00
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderSUVRETTA CAPITAL MANAGEMENT, LLC ($122.99M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOJerel A. Banks
Employees16
CountryUS
IPO Date2014-06-24

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Evommune, Inc. (EVMN)
  • XOMA Royalty Corp. (XOMA)
  • Rezolute, Inc. (RZLT)
  • Relmada Therapeutics, Inc. (RLMD)
  • Puma Biotechnology, Inc. (PBYI)
  • BioAge Labs, Inc. (BIOA)
  • Atea Pharmaceuticals, Inc. (AVIR)
  • Foghorn Therapeutics Inc. (FHTX)
BNTC earnings history · BNTC institutional & insider holders · BNTC KPIs & operating metrics · BNTC financials · BNTC investor presentations & press releases · BNTC SEC filings · BNTC peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.